問卷

TPIDB > Search Result

Search Result

篩選

List

16Cases

2024-08-01 - 2026-12-31

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2024-07-17 - 2026-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-07-01 - 2027-11-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-06-16 - 2029-09-30

Phase III

Active
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITYR Study)
  • Condition/Disease

    Bronchiectasis

  • Test Drug

    BI 1291583 or matching placebo

Participate Sites
6Sites

Recruiting6Sites

2024-07-01 - 2027-11-28

Phase III

An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)
  • Condition/Disease

    Idiopathic Pulmonary Fibrosis 、Progressive Pulmonary Fibrosis

  • Test Drug

    BI 1015550

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2024-08-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2